{"nctId":"NCT00736099","briefTitle":"Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM","startDateStruct":{"date":"2008-08"},"conditions":["Diabetes Mellitus, Type 2"],"count":2122,"armGroups":[{"label":"linagliptin 5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: linagliptine 5 mg"]},{"label":"linagliptin 5 mg and pioglitazone 30 mg","type":"EXPERIMENTAL","interventionNames":["Drug: linagliptine 5 mg and pioglitazone 30 mg"]}],"interventions":[{"name":"linagliptine 5 mg","otherNames":[]},{"name":"linagliptine 5 mg and pioglitazone 30 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Signed and dated written informed consent in accordance with the GCP and local legislation.\n2. Patients completing the entire treatment period as a double blind trial whether or not they have been treated with rescue medication.\n\nExclusion criteria:\n\n1. Patients who meet one or more of the withdrawal criteria of the treatment period of the previous trial.\n2. Pre-menopausal women (last menstruation =\\< 1 year prior to signing informed consent) who:\n\n   * are nursing or pregnant,\n   * or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, true sexual abstinence (when this is in line with the preferred and usual lifestyle of the patient; periodic abstinence \\[e.g. calendar, ovulation, symptothermal, post-ovulation methods\\] and withdrawal are not acceptable methods of birth control) and vasectomised partners. No exception will be made.\n3. Alcohol abuse within the 3 months prior to informed consent that would interfere with trial participation.\n4. Drug abuse which, in the opinion of the investigator, would interfere with trial participation.\n5. Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of the trial medication.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"82 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Frequency of Patients With Adverse Events (AEs)","description":"This includes any AEs detected during routine physical examination and electrocardiogram (ECG) procedures.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1253","spread":null},{"groupId":"OG001","value":"465","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"PRIMARY","title":"Frequency of Patients With Investigator-defined Hypoglycaemic Adverse Events","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"209","spread":null},{"groupId":"OG001","value":"86","spread":null}]}]}]},{"type":"PRIMARY","title":"Frequency of Patients With Significant Adverse Events Based on Standardised MedDRA Query (SMQ)","description":"As significant adverse events are considered: renal Aes (SMQ 'acute renal failure'), hypersensitivity reactions ('anaphylactic reactions' and 'angioedema'), hepatic Aes ('hepatitis, non-infectious', 'hepatic failure, fibrosis, cirrhosis and other liver damage-related conditions', 'liver-related investigations, signs and symptoms', 'cholestasis and jaundice of hepatic origin'), severe cutaneous adverse reactions ('severe cutaneous adverse reaction'), pancreatitis ('acute pancreatitis', 'chronic pancreatitis'').","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Frequency of Patients With Adjudication of Cardiac and Cerebrovascular Events","description":"Patients reported with cardiac and cerebrovascular events qualified for adjudication by the Clinical Event Committee (CEC)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Vital Signs","description":"Vital sign abnormalities (any abnormalities found during PE or ECG are reported with adverse events)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Haematology: Eosinophils","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 10%.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Haematology: Haemoglobin","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than or equal to 11.5 g/dL for male and as a value less than or equal to 9.5 g/dL for female patients.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Haematology: Haematocrit","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than or equal to 32%.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Haematology: Red Blood Cell Count","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 3 \\* 10\\^12/L.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Haematology: White Blood Cell Count","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 3 \\* 10\\^9/L (decrease) or a value greater than 20.1 \\* 10\\^9/L (increase).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Haematology: Platelets","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as value less than or equal to 75 \\* 10\\^9/L (decrease) or a value greater than or equal to 700 \\* 10\\^9/L (increase).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Clinical Chemistry: Potassium","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 3 mmol/L (decrease) or a value greater than 5.8 mmol/L (increase).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"135","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Clinical Chemistry: Uric Acid","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than 11 mg/dL for male and as a value greater than 10 mg/dL for female patients.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Clinical Chemistry: Triglycerides","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than 300 mg/dL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"329","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Clinical Chemistry: Amylase","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than 1.5 times the upper limit of normal (ULN).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Clinical Chemistry: Î³-Glutamyl-transferase (GGT)","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 3 times the ULN.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Clinical Chemistry: Creatinine","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 1.5 mg/dL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Clinical Chemistry: Creatinine Kinase","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 3 times the ULN.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Clinical Chemistry: Phosphate","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 0.7 mmol/L (decrease) or a value greater than 1.7 mmol/L (increase).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Clinical Chemistry: Calcium","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 1.8 mmol/L (decrease) or a value greater than 3 mmol/L (increase).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Clinical Chemistry: Sodium","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 130 mmol/L (decrease) or a value greater than 160 mmol/L (increase).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Clinical Chemistry: Alanine Transaminase (ALT)","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 3 times the ULN.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Clinical Chemistry: Aspartate Transaminase (AST)","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 3 times the ULN.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Clinical Chemistry: Glucose","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 54 mg/dL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Clinical Chemistry: Bilirubin","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 2 mg/dL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Clinical Chemistry: Alkaline Phosphatase (AP)","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 2 times the ULN.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Clinical Chemistry: Albumin","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 2.5 g/dL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Clinical Chemistry: Lactate Dehydrogenase (LDH)","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 3 times the ULN.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c From Baseline to Week 6","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.47"},{"groupId":"OG001","value":"-0.46","spread":"0.51"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c From Baseline to Week 18","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.63"},{"groupId":"OG001","value":"-0.63","spread":"0.72"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c From Baseline to Week 30","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.71"},{"groupId":"OG001","value":"-0.60","spread":"0.78"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c From Baseline to Week 42","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.65"},{"groupId":"OG001","value":"-0.53","spread":"0.78"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c From Baseline to Week 54","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"0.70"},{"groupId":"OG001","value":"-0.45","spread":"0.81"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c From Baseline to Week 66","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"0.73"},{"groupId":"OG001","value":"-0.44","spread":"0.85"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c From Baseline to Week 78","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"0.76"},{"groupId":"OG001","value":"-0.49","spread":"0.85"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With HbA1c<7.0% Over Time","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"382","spread":null},{"groupId":"OG001","value":"172","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With HbA1c<6.5% Over Time","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Lowered HbA1c by at Least 0.5% Over Time","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"175","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in FPG From Baseline to Week 6","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.21","spread":"30.54"},{"groupId":"OG001","value":"-15.17","spread":"30.84"}]}]}]},{"type":"SECONDARY","title":"Change in FPG From Baseline to Week 18","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.13","spread":"31.47"},{"groupId":"OG001","value":"-13.92","spread":"33.54"}]}]}]},{"type":"SECONDARY","title":"Change in FPG From Baseline to Week 30","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.52","spread":"31.84"},{"groupId":"OG001","value":"-16.17","spread":"33.00"}]}]}]},{"type":"SECONDARY","title":"Change in FPG From Baseline to Week 42","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.97","spread":"31.07"},{"groupId":"OG001","value":"-11.87","spread":"31.27"}]}]}]},{"type":"SECONDARY","title":"Change in FPG From Baseline to Week 54","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.44","spread":"30.52"},{"groupId":"OG001","value":"-12.62","spread":"30.96"}]}]}]},{"type":"SECONDARY","title":"Change in FPG From Baseline to Week 66","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.88","spread":"31.96"},{"groupId":"OG001","value":"-12.87","spread":"30.16"}]}]}]},{"type":"SECONDARY","title":"Change in FPG From Baseline to Week 78","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.90","spread":"34.11"},{"groupId":"OG001","value":"-13.64","spread":"31.67"}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Abnormalities in Clinical Chemistry: Cholesterol","description":"For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than 300 mg/dL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":158,"n":1532},"commonTop":["Hyperglycaemia","Hypoglycaemia","Nasopharyngitis","Upper respiratory tract infection","Urinary tract infection"]}}}